ANAB Stock Price, AnaptysBio Inc Quote, Chart

Market Summary

USD25.22+1.23

Market Closed

5.13%

ANAB Stock Price

View Fullscreen

ANAB RSI Chart

ANAB Valuation

Market Cap

689.0M

Price/Earnings (Trailing)

-4.22

Price/Sales (Trailing)

34.71

EV/EBITDA

-3.9

Price/Free Cashflow

-5.14

ANAB Price/Sales (Trailing)

ANAB Profitability

EBT Margin

-824.30%

Return on Equity

-341.79%

Return on Assets

-40.24%

Free Cashflow Yield

-19.47%

ANAB Fundamentals

ANAB Revenue

Revenue (TTM)

19.9M

Rev. Growth (Yr)

60.03%

Rev. Growth (Qtr)

126.9%

ANAB Earnings

Earnings (TTM)

-163.3M

Earnings Growth (Yr)

0.72%

Earnings Growth (Qtr)

-4.09%

Breaking Down ANAB Revenue

Last 7 days

-6.9%

Last 30 days

5.6%

Last 90 days

9%

Trailing 12 Months

23.3%

How does ANAB drawdown profile look like?

ANAB Financial Health

Current Ratio

11.53

ANAB Investor Care

Shares Dilution (1Y)

3.14%

Diluted EPS (TTM)

-6.14

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	19.9M	0	0	0
2023	14.4M	18.0M	20.6M	17.2M
2022	50.0M	36.7M	23.5M	10.3M
2021	71.2M	101.3M	122.2M	63.2M
2020	23.0M	18.0M	18.0M	75.0M
2019	0	7.5M	10.0M	8.0M
2018	0	0	3.3M	5.0M
2017	0	18.8M	13.0M	1.6M
2016	17.3M	17.1M	16.9M	16.7M
2015	0	0	0	17.6M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of AnaptysBio Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 26, 2024	faga daniel	sold (taxes)	-7,504,730	21.6	-347,441	ceo
Mar 25, 2024	faga daniel	sold	-64,267	21.4225	-3,000	ceo
Mar 22, 2024	faga daniel	sold	-3,325,180	22.7846	-145,940	ceo
Feb 16, 2024	loumeau eric j	sold	-125,000	25.00	-5,000	chief legal officer
Feb 16, 2024	loumeau eric j	acquired	70,100	14.02	5,000	chief legal officer
Jan 30, 2024	mulroy dennis	sold	-72,425	23.6298	-3,065	chief financial officer
Jan 08, 2024	loumeau eric j	sold	-50,272	21.81	-2,305	chief legal officer
Jan 08, 2024	lizzul paul f.	sold	-55,702	21.81	-2,554	chief medical officer
Jan 08, 2024	faga daniel	sold	-149,747	21.81	-6,866	ceo
Jan 08, 2024	mulroy dennis	sold	-47,545	21.81	-2,180	chief financial officer

Which funds bought or sold ANAB recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 13, 2024	Nuveen Asset Management, LLC	added	20.95	308,983	1,446,680	-%
May 13, 2024	Rafferty Asset Management, LLC	new	-	2,042,430	2,042,430	0.01%
May 13, 2024	XTX Topco Ltd	added	47.03	124,867	353,654	0.05%
May 13, 2024	Ameritas Investment Partners, Inc.	unchanged	-	1,663	34,050	-%
May 13, 2024	Balyasny Asset Management L.P.	reduced	-16.9	-51,266	354,600	-%
May 13, 2024	RENAISSANCE TECHNOLOGIES LLC	added	4.81	209,000	2,257,000	-%
May 13, 2024	AMERICAN INTERNATIONAL GROUP, INC.	reduced	-0.86	8,442	207,905	-%
May 13, 2024	FMR LLC	reduced	-30.57	-1,172,460	3,169,600	-%
May 13, 2024	UBS Group AG	added	242	1,043,560	1,445,020	-%
May 13, 2024	HRT FINANCIAL LP	sold off	-100	-1,620,000	-	-%

Are Funds Buying or Selling ANAB?

Are funds buying ANAB calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ANAB

No. of Funds

Unveiling AnaptysBio Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
May 06, 2024	frazier life sciences public fund, l.p.	2.2%	611,746	SC 13G
Feb 14, 2024	deep track capital, lp	7.67%	2,036,990	SC 13G/A
Feb 14, 2024	point72 asset management, l.p.	3.0%	788,545	SC 13G/A
Feb 14, 2024	tang capital partners lp	7.3%	1,950,609	SC 13G/A
Feb 13, 2024	vanguard group inc	5.19%	1,380,115	SC 13G/A
Jan 26, 2024	blackrock inc.	6.8%	1,799,823	SC 13G/A
Oct 02, 2023	deep track capital, lp	5.12%	1,360,176	SC 13G
Feb 14, 2023	point72 asset management, l.p.	7.5%	2,124,200	SC 13G/A
Feb 10, 2023	flynn james e	4.09%	1,161,826	SC 13G/A
Feb 09, 2023	federated hermes, inc.	4.93%	1,401,559	SC 13G/A

Recent SEC filings of AnaptysBio Inc

View All Filings

Date Filed	Form Type	Document
May 09, 2024	8-K	Current Report
May 09, 2024	10-Q	Quarterly Report
May 06, 2024	SC 13G	Major Ownership Report
Apr 24, 2024	DEFA14A	DEFA14A
Apr 24, 2024	DEF 14A	DEF 14A
Apr 24, 2024	ARS	ARS
Mar 26, 2024	4	Insider Trading
Mar 11, 2024	S-8	Employee Benefits Plan
Mar 11, 2024	8-K	Current Report
Mar 11, 2024	10-K	Annual Report

Peers (Alternatives to AnaptysBio Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	49.2B	6.8B	19.54%	-2.80%	-8.24	7.18	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.7B	2.0B	0.98%	-26.98%	-56.37	9.34	75.20%	68.82%
BMRN	15.1B	2.5B	-12.72%	-14.31%	73.61	6.12	13.74%	186.89%
INCY	12.8B	3.8B	6.98%	-11.75%	17.19	3.4	8.58%	129.81%
MID-CAP
BBIO	5.4B	107.9M	6.22%	110.41%	-9.93	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-16.95%	-51.10%	-11.99	9.55	394.93%	39.61%
AXSM	3.7B	251.0M	9.36%	-4.29%	-12.4	14.64	73.58%	-86.73%
ARWR	2.8B	240.7M	-10.69%	-43.90%	-6.04	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-11.38%	-29.25%	-1.4K	3.01	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	6.64%	20.67%	29.91	4.73	60.38%	-34.49%
NVAX	1.9B	996.6M	206.31%	55.15%	-4.75	1.9	-26.66%	65.49%
CRBP	456.3M	881.7K	5.07%	336.18%	-13.52	481.06	-77.61%	33.36%
INO	297.2M	4.9M	3.08%	29.79%	-2.38	61.07	-54.97%	48.23%
IBIO	16.2M	2.1M	-10.40%	79.21%	-0.7	7.61	-13.45%	69.54%

AnaptysBio Inc News

Latest updates

AnaptysBio Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2018Q4
Revenue	126.9%	7,179,000	3,164,000	4,854,000	4,653,000	4,486,000	6,576,000	2,262,000	1,107,000	1,059,000	1,011,000	20,890,000	30,027,000	11,247,000	60,000,000	-	-	15,000,000	3,000,000	-	5,000,000	-
Operating Expenses	-3.4%	49,380,000	51,140,000	41,050,000	43,603,000	45,775,000	32,781,000	30,926,000	29,015,000	32,719,000	32,168,000	27,653,000	30,560,000	29,608,000	26,655,000	24,336,000	22,635,000	25,253,000	25,258,000	33,745,000	31,657,000	19,663,000
S&GA Expenses	-100.0%	-	10,276,000	10,172,000	10,680,000	10,818,000	9,407,000	8,862,000	8,171,000	10,203,000	5,392,000	5,432,000	5,246,000	5,423,000	5,088,000	4,794,000	4,687,000	4,285,000	3,832,000	3,814,000	4,307,000	3,743,000
R&D Expenses	-	37,042,000	-	30,878,000	32,923,000	34,957,000	23,374,000	22,064,000	20,844,000	22,516,000	26,776,000	22,221,000	25,314,000	24,185,000	21,567,000	19,542,000	17,948,000	20,968,000	21,426,000	29,931,000	27,350,000	15,920,000
EBITDA Margin	13.6%	-8.21	-9.50	-6.22	-7.12	-8.87	-12.45	-2.43	-1.56	-1.14	-0.91	-0.16	-0.19	-	-	-	-	-	-	-	-	-
Interest Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4,000	200,000	240,000	281,000	365,000
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-22,000	-51,000	-60,000	-192,000
Earnings Before Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	33,646,000	-23,767,000	-21,548,000	-8,262,000	-20,285,000	-31,084,000	-24,022,000	-17,186,000
EBT Margin	13.6%	-8.24	-9.54	-6.26	-7.16	-8.92	-12.51	-2.46	-1.57	-1.16	-0.91	-0.16	-0.20	-	-	-	-	-	-	-	-	-
Net Income	-4.1%	-43,936,000	-42,211,000	-37,308,000	-39,845,000	-44,255,000	-26,413,000	-33,502,000	-32,554,000	-36,255,000	-32,538,000	-6,666,000	-429,000	-18,163,000	33,646,000	-23,767,000	-21,548,000	-8,262,000	-20,263,000	-31,033,000	-23,962,000	-16,994,000
Net Income Margin	13.7%	-8.23	-9.54	-7.19	-8.01	-9.47	-12.51	-5.74	-2.94	-1.52	-0.91	0.07	-0.09	-	-	-	-	-	-	-	-	-
Free Cashflow	-7.7%	-37,280,000	-34,629,000	-36,636,000	-25,599,000	-24,743,000	-10,860,000	-17,797,000	-24,225,000	-21,069,000	-25,315,000	-7,178,000	8,728,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-10.3%	406	452	487	517	552	610	619	604	625	643	424	427	396	417	385	402	424	435	452	480	494
Current Assets	-8.5%	372	407	428	439	437	447	450	453	512	554	387	398	387	397	346	385	371	378	425	431	422
Cash Equivalents	49.3%	54.00	36.00	26.00	35.00	95.00	71.00	59.00	72.00	166	496	336	332	284	251	209	221	165	171	183	147	106
Net PPE	-6.9%	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	1.00	2.00	2.00	2.00	1.00	2.00
Current Liabilities	-13.7%	32.00	37.00	39.00	42.00	36.00	26.00	21.00	20.00	20.00	16.00	21.00	21.00	14.00	20.00	24.00	20.00	23.00	30.00	30.00	31.00	25.00
Shareholder's Equity	-45.8%	48.00	88.00	120	148	191	262	278	304	331	356	384	386	382	397	360	381	401	405	421	448	468
Retained Earnings	-7.2%	-658	-614	-571	-534	-494	-450	-424	-390	-358	-321	-289	-282	-282	-263	-297	-273	-252	-244	-223	-192	-168
Additional Paid-In Capital	0.5%	706	703	695	687	689	718	708	699	691	679	673	668	664	661	658	654	652	649	644	641	637
Shares Outstanding	2.7%	27.00	27.00	27.00	27.00	27.00	29.00	28.00	28.00	28.00	27.00	27.00	27.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	367	-	-	-	400	-	-	-	489	-	-	-	556	-	-	-	1,391	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-8.5%	-37,253	-34,349	-36,474	-25,409	-24,568	-10,685	-17,747	-24,147	-21,014	-25,301	-7,006	9,591	-23,204	37,578	-17,013	-19,610	-15,112	-15,805	-22,096	-15,517	-16,099
Share Based Compensation	-23.7%	10,131	13,278	3,000	2,900	8,860	10,200	3,000	2,900	7,742	3,978	4,364	3,690	3,315	-	-	-	-	-	-	-	-
Cashflow From Investing	39.5%	68,616	49,178	30,635	-20,455	85,396	21,497	-32,434	-70,996	-312,912	-66,694	10,839	37,961	56,729	3,598	4,732	75,394	10,751	4,035	59,863	57,876	9,657
Cashflow From Financing	-164.3%	-13,633	-5,159	-3,072	-13,492	-37,574	1,949	37,027	432	4,609	251,336	241	554	167	126	263	71.00	-1,339	-111	-1,421	-1,660	-1,301
Buy Backs	100.0%	-	-229	-13.00	11,656	38,816	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ANAB Income Statement

2024-03-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Revenue from Contract with Customer, Product and Service [Extensible Enumeration]	Collaboration Revenue [Member]	Collaboration Revenue [Member]
Collaboration revenue	$ 7,179	$ 1,374
Operating expenses:
Research and development	37,042	34,957
General and administrative	12,338	10,818
Total operating expenses	49,380	45,775
Loss from operations	(42,201)	(44,401)
Other (expense) income, net:
Interest income	4,584	4,486
Non-cash interest expense for the sale of future royalties	(6,317)	(4,336)
Other expense, net	(2)	(4)
Total other (expense) income, net	(1,735)	146
Net loss	(43,936)	(44,255)
Unrealized gain on available for sale securities	173	1,979
Comprehensive loss	$ (43,763)	$ (42,276)
Net loss per common share:
Basic (in dollars per share)	$ (1.64)	$ (1.58)
Diluted (in dollars per share)	$ (1.64)	$ (1.58)
Weighted-average number of shares outstanding:
Basic (in shares)	26,801	27,953
Diluted (in shares)	26,801	27,953

ANAB Balance Sheet

2024-03-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 53,695	$ 35,965
Receivables from collaborative partners	7,089	6,851
Short-term investments	300,970	354,939
Prepaid expenses and other current assets	10,666	9,080
Total current assets	372,420	406,835
Property and equipment, net	1,954	2,098
Operating lease right-of-use assets	15,732	16,174
Long-term investments	15,473	27,026
Other long-term assets	256	256
Total assets	405,835	452,389
Current liabilities:
Accounts payable	4,582	4,698
Accrued expenses	25,903	30,967
Current portion of operating lease liability	1,813	1,777
Total current liabilities	32,298	37,442
Liability related to sale of future royalties	310,184	310,807
Operating lease liability, net of current portion	15,575	16,037
Stockholders’ equity:
Preferred stock, $0.001 par value, 10,000 shares authorized and no shares, issued or outstanding at March 31, 2024 and December 31, 2023, respectively	0	0
Common stock, $0.001 par value, 500,000 shares authorized, 27,317 shares and 26,597 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	27	27
Additional paid in capital	706,407	702,969
Accumulated other comprehensive loss	(624)	(797)
Accumulated deficit	(658,032)	(614,096)
Total stockholders’ equity	47,778	88,103
Total liabilities and stockholders’ equity	$ 405,835	$ 452,389

About AnaptysBio Inc

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 trial for the treatment of generalized pustular psoriasis; Rosnilimab, an anti-PD-1 agonist antibody program designed to suppress T-cell driven inflammatory diseases by augmenting signaling through PD-1 or targeted depletion of PD-1+ T cells; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

CEO	Mr. Daniel R. Faga
WEBSITE	anaptysbio.com
INDUSTRY	Biotechnology
EMPLOYEES	96

AnaptysBio Inc Frequently Asked Questions

What is the ticker symbol for AnaptysBio Inc? What does ANAB stand for in stocks?

ANAB is the stock ticker symbol of AnaptysBio Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of AnaptysBio Inc (ANAB)?

As of Mon May 13 2024, market cap of AnaptysBio Inc is 655.37 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ANAB stock?

You can check ANAB's fair value in chart for subscribers.

What is the fair value of ANAB stock?

You can check ANAB's fair value in chart for subscribers. The fair value of AnaptysBio Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of AnaptysBio Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ANAB so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is AnaptysBio Inc a good stock to buy?

The fair value guage provides a quick view whether ANAB is over valued or under valued. Whether AnaptysBio Inc is cheap or expensive depends on the assumptions which impact AnaptysBio Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ANAB.

What is AnaptysBio Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon May 13 2024, ANAB's PE ratio (Price to Earnings) is -4.01 and Price to Sales (PS) ratio is 33.02. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ANAB PE ratio will change depending on the future growth rate expectations of investors.